INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference Boca Raton, FL

Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

Raton, FL, Aug. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio (NASDAQ: INMB), a clinical-stage immunology company focused on developing

treatments that harness a patient's immune system to fight disease, announced today that RJ Tesi, MD, CEO and David Moss, Chief

Financial Officer, will present a corporate overview at the BTIG Virtual Biotechnology Conference being held on August 7 - 8, 2023.

Tesi and Mr. Moss will be available for one-on-one meetings. To register for the conference, contact your BTIG sales representative.

a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune

system to fight disease. INmune Bio has two product platforms that are both in clinical trials: The Dominant-Negative Tumor Necrosis

Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate

immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can

treat cancer (INB03 ), Early Alzheimer's disease, and treatment-resistant depression (XPro ). The Natural Killer Cell

Priming Platform includes INKmune developed to prime a patient's NK cells to eliminate minimal residual disease in patients

with cancer. INmune Bio's product platforms utilize a precision medicine approach for the treatment of a wide variety of hematologic

and solid tumor malignancies, and chronic inflammation. To learn more, please visit www.inmunebio.com.

trials are in early stages and there is no assurance that any specific outcome will be achieved. Any statements contained in this press

release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities

Litigation Reform Act of 1995. Any statements contained in this press release that do not describe historical facts may constitute

forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements

contained herein are based on current expectations but are subject to a number of risks and uncertainties. Actual results and the timing

of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these

risks and uncertainties. INB03 , XPro1595 (XPro ), and INKmune are still in clinical trials or preparing to start

clinical trials and have not been approved by the US Food and Drug Administration (FDA) or any regulatory body and there cannot be any

assurance that they will be approved by the FDA or any regulatory body or that any specific results will be achieved. The factors that

could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties

relating to the Company's ability to produce more drug for clinical trials; the availability of substantial additional funding

for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization;

and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.

These and other factors are identified and described in more detail in the Company's filings with the Securities and Exchange Commission,

including the Company's Annual Report on Form 10-K, the Company's Quarterly Reports on Form 10-Q and the Company's

Current Reports on Form 8-K. The Company assumes no obligation to update any forward-looking statements in order to reflect any event

or circumstance that may arise after the date of this release.

(516) 842-9614 Ext: 823